Aug 7 |
Amgen Stock Slides on Lowered Guidance
|
Aug 7 |
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
|
Aug 7 |
Why Amgen Stock Is Down Today Despite Solid Q2 Results
|
Aug 7 |
Amgen, Airbnb fall; Fortinet, Dynatrace rise, Wednesday, 8/7/2024
|
Aug 7 |
Heard on the Street: It Isn’t Time for Novo Nordisk to Worry About Wegovy Yet
|
Aug 7 |
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
|
Aug 7 |
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
|
Aug 7 |
Amgen cut at Wells Fargo; says obesity success is already priced in
|
Aug 7 |
Amgen: Shows Why Dividend Investing Is Getting Tougher
|
Aug 7 |
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
|